HCPCS G9829: Breast Adjuvant Chemotherapy Administered - OpenPayer

Summary & Overview

HCPCS G9829: Breast Adjuvant Chemotherapy Administered

HCPCS Level II code G9829 identifies administration of breast adjuvant chemotherapy, the systemic treatment given after primary surgical management to lower recurrence risk. This code matters nationally because adjuvant chemotherapy is a common, guideline-directed component of breast cancer care and represents a significant and recurring outpatient oncology service with implications for utilization, coverage policy, and payment across payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for the code, typical sites of service, and payer coverage considerations. The publication summarizes available benchmarks for utilization and payment where present, highlights relevant policy and billing considerations affecting claim adjudication, and outlines common modifiers reported with outpatient chemotherapy administration. Clinical context explains when adjuvant chemotherapy is used and its role in breast cancer care pathways. Where specific input data are not provided, the text notes "Data not available in the input."

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG9829HCPCS Level IIbreast adjuvant chemotherapyoncologyinfusion servicesoutpatient chemotherapybillingadministration codes

Billing Code Overview

HCPCS Level II code G9829 denotes breast adjuvant chemotherapy administered. This service represents administration of adjuvant systemic chemotherapy for breast cancer following primary surgical treatment to reduce risk of recurrence.

Service type: Chemotherapy administration (breast adjuvant)
Typical site of service: Outpatient oncology infusion center or hospital outpatient department

Clinical & Coding Specifications

Clinical Context

A typical patient is a woman with early-stage or locally advanced invasive breast carcinoma who has undergone definitive surgery (lumpectomy or mastectomy) and is prescribed systemic adjuvant chemotherapy to reduce recurrence risk. The oncology clinic or infusion center schedules the patient for serial intravenous chemotherapy sessions administered by an oncology-certified registered nurse under supervision of a medical oncologist. Prior to each cycle the patient undergoes chemotherapy consent, review of labs (complete blood count, metabolic panel), vital signs, and toxicity assessment. Central venous access (port-a-cath) or peripheral IV is used depending on regimen and venous access. Antiemetics, premedications, and supportive care (growth factor, hydration) are given per protocol. Documentation includes diagnosis, chemotherapy agents, dose, cycle number, start and stop times, infusion site, consent, lot numbers, and any acute reactions. Typical sites of service are hospital outpatient departments and freestanding infusion centers; services may also occur in physician offices with appropriate infusion capability.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when work or complexity of the chemotherapy administration significantly exceeds typical requirements (rare for standard infusions; document justification).

HCPCS G8877: No Preoperative Minimally Invasive Breast Biopsy Attempt

HCPCS-G2173-URI-WITH-COMORBID-CONDITION

HCPCS G2173: URI Episode With Significant Comorbid Condition

HCPCS-G0323-BEHAVIORAL-HEALTH-CARE-MANAGEMENT-20-MIN-MONTH

HCPCS G0323: Behavioral Health Care Management, ≥20 Minutes/Month

HCPCS-G8584-NO-BETA-BLOCKER-AT-DISCHARGE

HCPCS G8584: No Beta-Blocker at Discharge

HCPCS-G0058-LOWER-EXTREMITY-JOINT-REPAIR-CARE-IMPROVEMENT

HCPCS G0058: Improving Care for Lower Extremity Joint Repair, MIPS VA Pathway

HCPCS-G3002-CHRONIC-PAIN-MANAGEMENT-MONTHLY-BUNDLE

HCPCS G3002: Chronic Pain Management Monthly Bundle

HCPCS-G2118-FRAILTY-ENCOUNTER-AGE-81-PLUS

HCPCS G2118: Frailty Encounter for Patients Age 81 and Older

HCPCS-G9094-RECTAL-CANCER-ADENOCARCINOMA-METASTATIC-STATUS

HCPCS G9094: Rectal Cancer, Invasive Adenocarcinoma with Metastatic or Recurrent Disease

HCPCS-G1018-CLINICAL-DECISION-SUPPORT-MECHANISM-INFINX

HCPCS G1018: Clinical Decision Support Mechanism Infinx

HCPCS-G0067-DENTISTRY-MIPS-SPECIALTY-SET

HCPCS G0067: Dentistry MIPS Specialty Set

Showing 1–10 of 1996

23

Taxonomy Code	Specialty	Notes
`208000000X`	Medical Oncology	Primary specialty managing systemic adjuvant chemotherapy regimens.
`207Q00000X`	Hematology/Oncology	Often combined hematology/oncology providers manage chemotherapy selection and dosing.
`363L00000X`	Registered Nurse (Infusion)	Oncology-certified RNs perform infusion administration, monitoring, and documentation.
`208D00000X`	Surgical Oncology	Performs definitive breast surgery prior to adjuvant chemotherapy and coordinates systemic therapy timing.
`364S00000X`	Nurse Practitioner	Advanced practice clinicians who may order and manage chemotherapy under supervision or collaboration.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C50.911`	Malignant neoplasm of unspecified site of right female breast	Common primary diagnosis indicating invasive breast cancer treated with adjuvant chemotherapy.
`C50.912`	Malignant neoplasm of unspecified site of left female breast	Indicates invasive breast cancer of the left breast requiring systemic adjuvant therapy.
`C50.919`	Malignant neoplasm of unspecified site of unspecified female breast	Used when laterality is unspecified in documentation but adjuvant chemotherapy is indicated.
`C50.211`	Malignant neoplasm of upper-inner quadrant of right female breast	Anatomic-specific breast cancer site; adjuvant chemotherapy may be indicated based on stage and receptor status.
`C50.221`	Malignant neoplasm of upper-inner quadrant of left female breast	Anatomic-specific left breast cancer; used in treatment planning for adjuvant systemic therapy.
`C79.81`	Secondary malignant neoplasm of breast	Rarely used when breast is a metastatic site from another primary; systemic therapy decisions may include breast-directed agents.
`D05.90`	Unspecified type of carcinoma in situ of unspecified breast	In select high-risk or extensive cases, adjuvant systemic therapy considerations may arise; generally for invasive disease codes are primary.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Used for many standard IV chemotherapy infusions of short duration per cycle; often billed for each qualifying infusion session.
`96415`	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary infusion)	Billed in addition to the primary infusion code when infusion duration exceeds the first hour.
`96417`	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion of a new drug, up to 1 hour	Used when multiple separate IV chemotherapy agents are infused sequentially during the same visit.
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Used for concurrent non-chemotherapeutic infusions (eg, hydration, antiemetic infusions) that accompany chemotherapy when billed separately.
`36415`	Collection of venous blood by venipuncture	Performed pre-cycle to obtain necessary labs for pretreatment assessment; commonly billed alongside chemotherapy administration.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal antineoplastic	Used when part of the adjuvant regimen includes subcutaneous or intramuscular chemotherapeutic agents rather than IV.

OpenPayer